Apelin (APLN) is a recently discovered adipokine involved in the regulation of various metabolic functions. Its receptor, APLNR, is expressed in reproductive tissues, however, its role in human ovarian cells is unknown. In this study, we identified APLN and APLNR in human ovarian follicles and analyzed their expression in granulosa cells and follicular fluid obtained from obese and nonobese patients, with or without polycystic ovary syndrome (PCOS). We also investigated the effect of APLN on steroidogenesis in cultured human luteinized granulosa cells (hGCs) from nonobese patients without PCOS. Using RT-PCR and immunoblotting, we found that APLN and APLNR were expressed in hGCs and cumulus and theca cells. We confirmed these data immunohistochemically and observed that APLNR and APLN are present in human oocytes at different stages of follicular development. In patients with PCOS, we observed that follicular fluid APLN concentration and granulosa cell APLN and APLNR mRNA expression was higher than that observed in control patients. In cultured hGCs from nonobese patients without PCOS, insulin-like growth factor 1 (IGF1) increased APLNR expression, and recombinant human APLN (APLN-13 and APLN-17) increased both basal and IGF1-induced steroid secretion. These effects on steroid production were reversed when cultured in the presence of ML221, an APLNR antagonist, which was associated with an increased 3beta-hydrosteroid dehydrogenase (HSD3B) protein concentration. We showed that these effects were dependent on the activation of the AKT and MAPK3/1 pathways using pharmacological inhibitors. Our results show that APLN and APLNR are present in human ovarian cells and APLN increases IGF1-induced steroidogenesis in granulosa cells through an increase in HSD3B protein expression and activation of the MAPK3/1 and Akt pathways. Therefore, APLN and APLNR may play a role in human follicular development and the pathogenesis of PCOS.
INTRODUCTION
Apelin (APLN) is a peptide hormone recently identified in bovine stomach extracts [1] . Several active isoforms of APLN have been identified to date. The human preproapelin gene encodes a 77-amino acid preproprotein that is cleaved to several active forms, including APLN-36, APLN-17, APLN-13, and the pyroglutamyl form of APLN-13 (Pyr-APLN13) [2] . Of these, the 36-amino acid isoform is the most widely expressed, although the shorter isoforms are more potent and more abundant in the circulation [3, 4] . Unlike most other GPCR (G protein-coupled receptor) families, APLN appears to carry out its effects by binding to only one receptor subtype, the G i protein-coupled, angiotensin receptor-like receptor APLNR [1] . The APLN receptor (also known as APLNR and AGTRL1) is a class A GPCR, which was discovered in 1993 based on its sequence similarity with the angiotensin AT 1 receptor [5] . APLNR did not bind angiotensin II and, therefore, remained an orphan receptor until the identification of APLN as an endogenous ligand in 1998 [1] . Upon binding to APLNR, APLN modulates various signaling pathways in different cell types, including the recruitment of b-arrestin, a protein that initiates receptor internalization as well as downstream signaling pathways in addition to MAPK3/1, AKT, and PRKA signaling pathways [6] [7] [8] [9] . The three latter signaling pathways have previously been associated with the molecular mechanisms of adipokines in somatic gonadal cells [10] [11] [12] .
APLN and APLNR mRNA is widely expressed in several rat and human tissues, including the heart, brain, stomach, placenta, and breast (for a review, see [8] ). APLN is also present in, and secreted by, human and murine adipocytes, suggesting that it is an adipokine [9, 13] . The APLN/APLNR system is implicated in several different key physiological processes, such as angiogenesis, cardiovascular function, fluid homeostasis, cell proliferation, and food intake and regulation of energy metabolism [14] [15] [16] . It is also involved in the development and progression of different pathologies including diabetes, obesity, cardiovascular disease, and cancer [8, 17, 18] . Indeed, studies in both humans and animals have shown that plasma APLN concentrations are usually increased in individuals with obesity and type 2 diabetes (for a review, see [2] ). APLN and APLNR are also expressed in reproductive tissues including the ovary and pituitary. In male rats, intracerebroventricular infusion of APLN-13 has been shown to decrease testosterone release by suppressing LH secretion, suggesting that APLN could play a role in the central regulation of fertility [19] . In the bovine ovary, APLN and APLNR expression was identified in the corpus luteum, and their expression decreased at the end of the luteal phase and dropped steeply during corpus luteum regression [20] . The APLN/APLNR system may also have other physiological roles in vascular establishment, maturation, and maintenance in the corpus luteum during the estrous cycle. APLN and APLNR are also expressed in bovine follicles [20] [21] [22] . Furthermore, APLNR is present in bovine granulosa cells, where progesterone increases its expression [21] . The expression of APLN and APLNR in mature follicles suggests that the APLN/APLNR system could play an important role in follicle selection and dominance in the cow [21] .
Despite these advances, there are still questions regarding the expression of APLN and APLNR in the human ovary, in addition to the relationship of APLN with ovarian cell functionality. Furthermore, all studies to date have described serum APLN concentrations in relation to the hormonal and metabolic profile in patients with and without polycystic ovary syndrome (PCOS) [23] [24] [25] . However, no studies have reported the concentration of APLN and APLNR in human ovarian cells. PCOS is one of the major causes of anovulatory infertility in women [26] . In this study, we studied APLN and APLNR expression in human ovarian cells for the first time, and the effect of recombinant human (rh) APLN (APLN-17 and ALPN-13) on steroid production in primary luteinized human granulosa cells (hGCs). We also determined the expression of APLN and APLNR in granulosa cells from obese and nonobese patients with or without PCOS.
MATERIALS AND METHODS

Patients
This collaborative study was performed at the Institut National de la Recherche Agronomique and the Department of the Biology of Reproduction, CHRU Bretonneau. Ethical approval for this study was obtained from the Research Ethics Board of the CHRU Bretonneau, and written informed consent was obtained from all patients. No patients received any monetary compensation for participating in the study, and all patients gave written informed consent before the use of cells. For the culture of primary hGCs, 70 infertile women (36 6 4 yr) undergoing in vitro fertilization (IVF) with intracytoplasmic sperm injection were recruited in 2013 and 2014. The causes of infertility were mechanical or male factor infertility, without any known endocrinopathy such as PCOS, hypo-and hypertrophism, or hyperprolactinemia. One cycle from each patient was included in the study. We investigated the follicular APLN concentration in four groups of patients: nonobese (body mass index [BMI] of 18-25) without PCOS (n ¼ 50), nonobese with PCOS (n ¼ 30), obese (BMI . 30) without PCOS (n ¼ 15), and obese with PCOS (n ¼ 30). The expression of APLN and APLNR mRNA in granulosa cells was determined in eight patients from each group. The PCOS diagnosis was established according to the Rotterdam criteria (oligomenorrhea and/or anovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasonography scan as well as exclusion of other etiologies that mimic the PCOS phenotype) [27] . A patient was considered to have PCOS if she fulfilled two of the three criteria mentioned above. Oligomenorrhea was defined as irregular menstrual bleeding occurring less than six times a year. Each PCOS subject had enlarged polycystic ovaries as determined by ultrasound. The antral follicle count per ovary was greater than 12 in all subjects. None of the follicles exceeded 9 mm in diameter, and the vast majority were 2-5 mm in size. Normal women (without PCOS) did not exhibit enlarged ovaries, had antral follicle counts of 7-10 per ovary, and had no follicles greater than 10 mm in diameter. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) from adult women (nonobese and nondiabetic) were obtained from Tebu-Bio and used as the positive control.
Hormones and Reagents
Recombinant human APLN-13 and ALPN-17 were purchased from Abcam and R&D Systems, respectively. Purified ovine FSH-20 (oFSH; lot no. AFP-7028D, 4453 IU/mg, FSH activity ¼ 175 times the activity of oFSH-S1) was a gift from National Institute of Diabetes and Digestive and Kidney Diseases (National Hormone and Pituitary Program). Recombinant human insulin-like growth factor-I (IGF-I) and LH used for the cell culture treatment were obtained from Sigma-Aldrich. ML221 was purchased from R&D Systems. Both MEK1/ 2-specific inhibitor U0126 and PI3K/AKT-specific inhibitor LY293004 were from Calbiochem.
Antibodies
Rabbit polyclonal antibodies to human APLN and APLNR were obtained from Antibodies-Online and Sigma-Aldrich, respectively. Rabbit polyclonal antibodies to MAPK3/1 and MAPK14 (C20) were purchased from Santa Cruz Biotechnology. Rabbit polyclonal antibodies to phospho-MAPK14 (Thr180/ Tyr182), phospho-MAPK3/1 (Thr202/Tyr204), phospho-Akt (Ser 473), and phospho-PRKAA (Thr172) were purchased from New England Biolabs Inc. Rabbit polyclonal antibodies against PRKAA were obtained from Upstate Biotechnology Inc. CYP11A1 and STAR (steroidogenic acute regulatory protein) antibodies were a gift from Dr. Dale Buchanan Hales (University of Illinois) whereas HSD3B antibodies were a gift from Dr. Van Luu-The (CHUL Research Center and Laval University). Mouse monoclonal antibodies to vinculin and CYP19A1 were purchased from Sigma-Aldrich and Serotec, respectively. All antibodies were diluted to 1:1000 for use in the Western blot experiments.
Isolation and Culture of hGCs
Human GCs were obtained from pre-ovulatory follicles from women undergoing IVF after oocyte retrieval. The cells and follicular fluid (FF) collected from multiple follicles were pooled for each patient. The ovarian stimulation protocol and IVF and intracytoplasmic sperm injection procedures used have been previously reported [12, 28] . After isolation of cumulus oocyte complexes, FFs were centrifuged for 10 min at 400 3 g in order to recover the cell pellet. The hGCs were isolated from red blood cells with a 20 min centrifugation at 400 3 g on two layers of discontinuous Percoll gradient (40% and 60% Percoll in Hams medium; Gibco-BRL, Life Technologies). In order to obtain better purification of hGCs, the 40% fraction was treated with hemolytic medium (10 mmol/L NH 4 Cl in Tris HCl, pH 7.5) (Sigma-Aldrich). Cells were then washed with fresh medium (Ham F12 medium), counted in a hemocytometer, and cell viability was determined using the trypan blue dye exclusion method. Finally, hGCs were either frozen at À808C for mRNA and protein analyses or cultured in McCoy 5A medium supplemented with 20 mmol/L Hepes, penicillin (100 IU/ml), streptomycin (100 mg/ml), L-glutamine (3 mmol/L), 0.01% BSA, 0.1 lmol/L androstenedione, 5 mg/L transferrin, 20 lg/L selenium, and 5% fetal bovine serum. After 48 h, cultured cells were starved for 24 h then incubated in fresh medium and cultured with or without the treatment for the specified time. All cultures were performed in a watersaturated atmosphere containing 95% air and 5% CO 2 at 378C. For each experiment, all treatments were applied to three or four independent culture cells.
Follicular Fluid Sample Preparation
On the day of oocyte retrieval, the collection system (needle and tubing) was rinsed with culture medium prior to aspiration. All FF samples collected were pooled for each patient. A volume of 25 ml from each FF sample pool was centrifuged at 3000 3 g for 15 min. The supernatant was removed and filtered through 0.45 lm filters to eliminate cell debris, then stored at À808C.
KGN Cell Culture
The human ovarian granulosa-like tumor cell line KGN was cultured in Dulbecco minimal essential medium-F12 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum and antibiotics (100 IU/ml penicillin and 100 lg/ml streptomycin) in a 5% CO 2 atmosphere at 378C. KGN cells were obtained in 2002 from Dr. Masatoshi Nomura and Dr. Hajime Nawata (Kyushu University [29] ). KGN cells are undifferentiated and maintain the physiological characteristics of ovarian cells, including expressing the functional FSH receptor and CYP19A1 [29] .
APLN FF Levels
APLN-13 was measured in the FF samples, collected during transvaginal oocyte retrieval, using a commercially available competitive enzyme-linked immunoassay (ELISA) kit (Holzel Diagnostika). The ELISA assay had a low sensitivity limit of 0.075 ng/ml (range from 0-8 ng/ml) and intra-and interassay coefficients of variation of less than 5% and 14%, respectively.
RNA Isolation and Real-Time Polymerase Chain Reaction
Total RNA was extracted from hGCs and VAT or SAT using the Trizol reagent, according to the manufacturer's instructions (Fisher Scientific). The reverse transcription (RT) of total RNA (1 lg) was performed by denaturing the RNA, which then underwent RT in a 20 ll reaction mixture containing 50 mM ROCHE ET AL.
Tris-HCL (pH 8.3), 75 mM KCL, 3 mM MgCl 2 , 200 lM of each deoxynucleotide triphosphate, 50 pmol of oligo (dT), 15.5 U of ribonuclease (RNase) inhibitor, and 15 U of Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Promega). The mixture was incubated for 1 h at 378C, then polymerase chain reaction (PCR) was performed in a 50 ll reaction mixture containing 10 mM Tris-HCL (pH 9.0), 50 mM KCl, 1.5 mM MgCl 2 , 200 mM of each deoxynucleotide triphosphate, 10 pmol of each primer, 1 U of Taq polymerase, and 2 ll of the RT mixture. We used specific primer pairs for APLN (forward 5 0 -TGGTGTCTAGCAAGACCCTG-3 0 and reverse 5 0 -GCAGTGA CA TGTGGTCTCGG-3 0 ) and APLNR (forward 5 0 -CTATCCTGTTTTCTGAGTGTGAGG-3 0 and reverse 5 0 -CTAAGGGCTG GAGCACTAATTATC-3 0 ). The samples were denatured and processed (958C for 1 min, 588C for 1 min, then 728C for 1 min), with a final extension step at 728C for 10 min. The PCR products were run on an agarose gel (1.5 %), which was stained with ethidium bromide. The DNA fragment of interest was isolated and then sequenced by Genome Express. All RT-PCR consumables were purchased from Sigma-Aldrich and the M-MLV reverse transcriptase and RNase inhibitor (RNasin) were obtained from Promega.
Real-Time Polymerase Chain Reaction
After the RT, the human cDNA obtained from the granulosa cells of obese or nonobese patients with or without PCOS were diluted 1:5. The 20 ll reaction mixture for real-time PCR contained 10 ll iQ SYBR Green supermix (BioRad), 0.25 ll of each primer (10 lM), 4.5 ll of water, and 5 ll of template. The cDNA templates were amplified and measured using the MyiQ real-time PCR system (Bio-Rad) with the following protocol: one cycle for 5 min at 958C to denature the sample, 40 cycles for 1 min at 958C for denaturation, 1 min at 608C for hybridization, 1 min at 728C for elongation, and then one cycle for 5 min at 728C for the final elongation. The gene expression was normalized using the geometric mean of three housekeeping genes (ACTB, RPL19, and PPIA), the expression of which was stable under these conditions (data not shown). The primers used were: ACTB, forward 5 0 -GCGGGAAATCGTGCGTGA CATT-3 0 and reverse 5 0 -GATGGAGTTGAAGGTAGTTTCGTG-3 0 ; RPL19, forward 5 0 -GGGCATAGGTAAGCGGAAGG-3 0 and reverse 5 0 -TCAGGTA CAGGCTGCCGA-3 0 ; and PPIA, forward 5 0 -AGCATGTGGTGTTTGG CAAA-3 0 and reverse 5 0 -TCGAGTTGTCCACAGTCAGC-3 0 . For APLN and APLNR, we used the same primers described in the previous section. The normalized values for relative expression (R) were calculated according to the following equation: R ¼ (E Gene ÀCT Gene )/(geometric mean (E PPIA ÀCT PPIA ; E ACTB ÀCT ACTB ; E Rpl19 ÀCT Rpl19 ), where CT was the cycle threshold and E was the PCR efficiency for each primer pair. The specificity of the amplified fragment sequence was controlled by Beckman Coulter Genomics. The efficiency was between 1.7 and 2.
Protein Extraction and Western Blot Analysis
Proteins were extracted from primary hGCs and VAT and SAT as described previously [30] . Lysates were centrifuged at 12 000 3 g for 30 min at 48C, and the protein concentration was determined using the bicinchoninic acid assay protein assay. Protein extracts were denatured, and samples were subjected to electrophoresis on a 12% SDS polyacrylamide gel, then transferred onto nitrocellulose membranes. Blots were blocked with 50 mM Tris and 150 mM NaCl containing 0.1% Tween 20 and 5% milk for 30 min at room temperature. Membranes were then incubated overnight at 48C with specific antibodies at a final dilution of 1:1000. Blots were washed several times and incubated at room temperature for 90 min with a horseradish peroxidase (HRP)-conjugated antirabbit or anti-mouse immunoglobulin G (IgG) (dilution 1:5000). The signal was detected by a chemiluminescence kit (Amersham ECL) using a G:Box-iChemie apparatus (Syngene; Ozyme) with the GeneSnap software (version 4.01.02; Syngene). The results are expressed as the intensity signal in arbitrary units after normalization by the total amount of MAPK1/3, MAPK14, AKT, and PRKAA proteins (for MAPK1/3, MAPK14, AKT, and PRKAA phosphorylation, respectively), and VINCULIN was used as an internal standard for APLN and APLNR. The effect of rh APLN-13 and APLN-17 was determined for four independent hGC cultures.
Immunohistochemistry
Human ovary sections from Interchim were deparaffinized, hydrated, and microwaved for 5 min in an antigen unmasking solution (Vector Laboratories Inc., AbCys), then allowed to reach room temperature. Sections were washed for 5 min in PBS then incubated in a peroxidase-blocking reagent for 10 min at room temperature in order to inhibit the endogenous peroxidase activity (DakoCytomation). After two 5-min washes in PBS, the nonspecific background was eliminated by blocking with 5% lamb serum in PBS for 20 min, followed by an overnight incubation at 48C with PBS containing a rabbit primary antibody raised against either APLN or APLNR (1:100). Sections were washed in PBS twice for 5 min each, then incubated for 30 min at room temperature with a ready-to-use labeled Polymer-HRP anti-rabbit antibody (EnVision Plus HRP system; DakoCytomation). The sections were washed in PBS twice, and the staining was revealed after incubation at room temperature with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB) (Liquid DAB þ Substrate Chromogen System; DakoCytomation). The negative controls were prepared by replacing the primary antibodies with rabbit IgG.
Progesterone and Estradiol ELISA Assays
Steroid concentration in the culture medium of hGCs cells was measured after an overnight serum starvation followed by 48 h of treatment by using ELISA assays (estradiol [Cayman Chemical, Interchim] and progesterone [31] ),The limit of detection for progesterone and estradiol were 12 and 1.5 pg/ tube, respectively. The intra-and interassay coefficients of variations were less than 7% and 9%, respectively. The results are expressed as the concentration of each steroid (ng/ml)/mg of protein per well. Data were obtained from three to four independent cultures, and each treatment (rh APLN-13 or APLN-17 and IGF1, LH, or FSH) had four replicates.
Statistical Analysis
All experimental data were expressed as the mean 6 SEM. A one-way analysis of variance (ANOVA) was used to determine any difference between treatments, except for the data reported in Figures 3 and 4 for which a two-way ANOVA was performed. P , 0.05 was considered to be statistically significant.
RESULTS
APLN and APLNR Expression in Human Ovarian Cells
We studied the expression (mRNA and protein) of APLN and its receptor, APLNR, in luteinized hGCs and in the human KGN cell line. As shown in Figure 1A , the PCR products for APLN and APLNR were obtained at the expected sizes of 200 and 89 bp, respectively. The specificity of the amplified products was assessed by sequencing. The partial sequences exhibited high homology (99%-100%) with human APLN and APLNR, respectively (data not shown). We used the expression in the VAT and SAT as positive controls. Similar results were observed for the APLN and APLNR protein concentrations, as determined by immunoblotting (Fig. 1B) . From the immunohistochemistry results, as performed using ovarian follicular sections from nonobese women without PCOS (age 34 6 2 yr), we confirmed that APLNR was present in granulosa cells, cumulus cells, oocytes, and less abundantly in the theca cells of the large follicles (Fig. 1C, a-c) . We also found APLNR in ovarian cells from primordial, primary, and secondary follicles (Fig. 1C, d-g ). APLN was detected in the primordial follicles, in granulosa cells, and oocyte of the primary follicles, and in granulosa cumulus and theca cells of the antral follicles (Fig.  1C, h-k) . In these latter follicles, APLN immunostaining was weak (Fig. 1Cj) . Thus, APLN and APLNR are expressed not only in hGCs, but also in cumulus and theca cells. They are also expressed in oocytes in human follicles at different stages of development.
Effect of IGF1, FSH, and LH on APLN and APLNR Expression in Primary hGCs
We determined whether IGF1, FSH, and LH hormones, which are known to be involved in ovarian functions, were able to regulate APLN and APLNR expression in primary hGCs. Cells starved overnight were incubated for 24 h with either IGF1 (10 À8 M), FSH (10 À8 M), or LH (10 À8 M). We observed that IGF1, FSH, and LH did not affect APLN mRNA expression (Supplemental Fig. S1 ; Supplemental Data are ROLE OF APELIN IN HUMAN GRANULOSA CELLS available online at www.biolreprod.org). However, we also showed that IGF1 increased APLNR mRNA expression after 24 h of stimulation, whereas FSH and LH had no effect ( Fig. 2A) . We also confirmed the effect of IGF1 on the APLNR protein concentration at different concentrations (10 À8 , 10 À9 , and 10 À10 M; Fig. 2B ). Thus, IGF1 increases APLNR expression in hGCs.
Effect of rh APLN-13 and APLN-17 on Steroid Secretion by Primary hGCs
We have previously shown that some adipokines can modulate steroid production in primary hGCs [10, 12, 30, 32] . Therefore, we investigated whether rh APLN-13 and APLN-17 could affect steroidogenesis in primary hGCs. Cells were incubated in serum-free media containing various concentrations (10 À9 , 10 À8 , and 10 À6 M) of rh APLN-13 (Fig. 3A) or rh APLN-17 ( Fig. 3C) (Fig. 3, B and D) . To confirm the specific effect of APLN, we preincubated hGCs with an APLNR antagonist, ML221 (Fig. 3, A and B) . The secretion of progesterone was increased by treatment with rh APLN-13 ( Fig. 3A) and rh APLN-17 ( Fig. 3C ) for 48 h in a dosedependent manner (P , 0.001). As shown in Figure 3A , the rh APLN-13-induced progesterone release was reversed when cultured in the presence of ML221 (10 lM). As expected, treatment with either the IGF1, FSH, or LH treatments alone increased progesterone secretion in primary hGCs (Fig. 3 , B and D) [33] . In the presence of IGF1, treatment with rh APLN-13 and rh APLN-17 (10 À9 M) produced a two-fold increase in the secretion of progesterone (P , 0.001; Fig. 3, B and D) , whereas no effect of rh APLN-13 or rh APLN-17 was observed in the presence of FSH or LH. For APLN-13, this effect was reversed by preincubating the cells with ML221 (10 lM; Fig.  3B ). Similar results were observed for the effect of rh APLN-13 and rh APLN-17 on estradiol secretion (Fig. 4) . We also investigated whether rh APLN-13 and APLN-17 could alter human antral (a-c, j) , secondary (f and g), primary (e, i), and primordial (d, h, k) ovarian follicles by immunohistochemistry. DAB-immunoperoxidase staining was performed on paraffin-embedded human ovary tissue using antibodies against APLNR (a-f) or APLN (h-j), or rabbit IgG (negative control; c, g, and k). The following abbreviations were used for cells derived from ovarian follicles at different stages of development: GC, granulosa cells; CC, cumulus cells; TC, theca cells; Oo, oocytes; and AT, antrum. Bars ¼ 100 lm. The arrows show primordial follicles (d, h, k) or primary follicles (e, i). Immunohistochemistry was performed on two different human ovary slides from each of the four nonobese patients without PCOS.
ROCHE ET AL. hGC proliferation by [
3 H]-thymidine incorporation and cell viability as measured by staining with trypan blue. Recombinant human APLN-13 and APLN-17 did not affect cell proliferation (Supplemental Fig. S2 ) or cell viability (data not shown) in the basal state or in response to IGF1, FSH, or LH. Thus, rh APLN-13 and APLN-17 increased IGF1-induced progesterone and estradiol production without affecting the proliferation and viability of hGCs.
Effect of rh APLN-13 and APLN-17 on the Concentration of Steroidogenesis Enzymes and the Cholesterol Carrier STAR
To better understand how rh APLN-13 and rh APLN-17 affect IGF1-induced steroidogenesis in hGCs, we investigated the effect of these molecules on the concentration of three important steroidogenesis enzymes, CYP11A1, HSD3B, and CYP19A1, in addition to the concentration of STAR, which is an important cholesterol transporter. As shown in Figure 3 , E and F, treatment with rh APLN-13 (10 À9 M) and rh APLN-17 (10 À9 M) significantly increased the protein levels of HSD3B in both the presence and absence of IGF1 (10 À8 M). Furthermore, an additive effect was observed when IGF1 and rh APLN-13 or rh APLN-17 were combined. Conversely, treatment with rh APLN-13 or APLN-17 (10 À9 M) did not affect the concentrations of STAR, CYP11A1, or CYP19A1 in the presence or absence of IGF1 (Supplemental Fig. S3 ).
Effect of rh APLN-13 and APLN-17 on Signaling Pathways in hGCs
APLN is known to activate various signaling pathways in different cell types [6, 34, 35] . Therefore, we investigated the effect of rh APLN-13 and APLN-17 (10 À9 M) on the phosphorylation of MAPK1/3, MAPK14, AKT, and PRKAA over different exposure periods. We focused on these pathways because they have previously been shown to be regulated by adipokines in somatic gonadal cells [10] [11] [12] . As shown in Figure 5 , A and B, rh APLN-13 (10 À9 M) significantly reduced the phosphorylation of MAPK14 after 10 min of stimulation, whereas it activated AKT under the same conditions. Phosphorylation of MAPK3/1 was rapidly increased after 1 min of stimulation, but this activation was transient (Fig. 5C) . No significant variation in phosphorylation was observed for the PRKAA signaling pathway in response to rh APLN-13 (10 À9 M) (Fig. 5D) . Thus, rh APLN-13 transiently activates AKT and MAPK3/1 but inhibits MAPK14 in hGCs. Similar results were observed for rh APLN-17 (Supplemental Fig. S4 ).
We then investigated the molecular mechanisms involved in the observed effect of rh APLN-13 on steroid production in response to IGF1 in hGCs. Specifically, we determined whether rh APLN-13 treatment could modulate IGF1 receptor (IGF1R) signaling. The hGCs were incubated in serum-free media supplemented with rh APLN 17 (10 À9 M) for 48 h, which were the same conditions used to measure steroid production, in either the presence or absence of IGF1 (10 À8 M) treatment for 10 min for AKT (Fig. 5E) and MAPK14 (Fig. 5F ) and 1 min for MAPK3/1 (Fig. 5G ) phosphorylation studies. As expected, treatment with IGF1 alone increased the phosphorylation of AKT (Fig. 5E ) and MAPK3/1 (Fig. 5G) , whereas no effect was observed for MAPK14 phosphorylation (Fig. 5F ). Treatment with only rh APLN-13 also increased the basal phosphorylation of AKT and MAPK3/1 and reduced that of MAPK14. Furthermore, an additive effect of rh APLN-13 and IGF1 was observed for AKT and MAPK3/1 phosphorylation but not for MAPK14 phosphorylation when the two hormones were combined (Fig. 5, E-G) . To demonstrate the involvement of the MAPK3/1 and AKT signaling pathways in the observed effect of APLN-13 on progesterone production and HSD3B protein levels in the absence or in the presence of IGF1, we used the two pharmacological inhibitors U0126 (10 lM) and LY293004 (10 lM) known to block the MAPK1/3 and AKT signaling pathways, respectively. As shown in Figure 6 , U0126 
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and LY293004 significantly reduced progesterone production (Fig. 6A ) and HSD3B protein levels (Fig. 6B ) in response to rh APLN-13 in the presence or absence of IGF1. Thus, these data suggest that both MAPK3/1 and AKT are involved in the APLN-13-induced steroid synthesis in basal state and in response to IGF1.
Follicular Fluid APLN-13 Concentration and APLN and APLNR mRNA Expression in hGCs from Obese or Nonobese Subfertile Women with or Without PCOS
We investigated the APLN-13 concentration in the FF and the mRNA expression of APLN and APLNR in hGCs from obese or nonobese women, with or without PCOS. The control group (nonobese without PCOS) was referred to IVF due to male or tubal factors. The age of patients did not significantly differ between the four groups (nonobese without PCOS, 33 6 0.6 yr; obese without PCOS, 34 6 1 yr; nonobese with PCOS, 32 6 1.2 yr; and obese with PCOS, 32 6 1.5 yr). For each group, the mean BMI was: 21.4 6 0.2 in nonobese women without PCOS, 33.3 6 0.7 in obese women without PCOS, 21.1 6 0.3 in nonobese women with PCOS, and 32.5 6 0.7 in obese women with PCOS. As shown in Figure 7A , the APLN concentrations in the FF were significantly higher in patients with PCOS than control patients. Furthermore, in both the PCOS and control groups, the obese patients had higher APLN-13 levels in the FF. As shown in Figure 7 , B and C, both APLN and APLNR mRNA expression in the granulosa cells of PCOS patients were significantly higher than those observed in patients without PCOS (control and obese patients). Furthermore, in the PCOS groups, granulosa cells from obese patients had significantly higher APLN and APLNR mRNA expression than those from nonobese patients (Fig. 7, B and C). In contrast, in the non-PCOS groups, APLN mRNA expression in hGCs from obese patients was lower compared to nonobese patients (Fig. 7B) , while the APLNR mRNA expression levels were similar (Fig. 7C) . The culture medium was then collected and analyzed for progesterone content. The results are expressed as protein concentration per well (ng/ml). The results are presented as the mean 6 SEM of three independent groups of hGCs collected from six patients. Bars with different letters are significantly different (P , 0.05). E-F) Effect of rh APLN-13 (E) or rh APLN-17 (F) on basal and IGF1-stimulated HSD3B protein levels in hGCs. Human GCs were cultured for 48 h in media containing serum, then cultured for 48 h in serum-free media containing either rh APLN-13 or rh APLN-17 (10 À9 M) in the absence or presence of IGF-I (10 À8 M). Protein extracts from human GCs were analyzed by immunoblotting using antibodies against the HSD3B protein. Equal protein loading was verified by reprobing the membranes with an anti-VINCULIN antibody. The results were representative of at least three independent experiments. Blots were quantified, and the HSD3B to VINCULIN ratio is shown. The results are expressed as mean 6 SEM. Different letters indicate significant differences (P , 0.05).
DISCUSSION
In the present study, we report for the first time that APLN and APLNR are expressed in different ovarian cells from human follicles (granulosa cells, theca cells, and oocytes). In oocytes, APLNR and APLN were found to be expressed from the primordial stage. The concentration of APLN-13 in the FF and APLN and APLNR expression in hGCs was higher in patients with PCOS than control patients. In primary hGCs from control patients (nonobese patients without PCOS) we showed that rh IGF1 increases APLNR mRNA and protein expression in a dose-dependent manner but does not affect APLN expression. Furthermore, rh APLN (13 and 17) increases progesterone and estradiol secretion in a dose-dependent manner in the basal state and in response to IGF1. These effects were found to be reversed by the addition of ML221, an antagonist of APLNR. This was associated with an increase in HSD3B protein concentration and AKT and MAPK3/1 phosphorylation. Using pharmacological inhibitors, our data showed that the positive effects of rh APLN-13 on the progesterone production and HSD3B protein level were dependent on the activation of the AKT and MAPK3/1 pathways We detected APLN and APLNR in human ovarian follicles, especially in granulosa, cumulus, and theca cells. Furthermore, we found the presence of APLNR and APLN (although weak) in oocytes. More studies are necessary to investigate the importance of APLN in the oocyte during the human follicular development. APLNR and APLN mRNA and protein have previously been identified in the ovaries of other species 
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including rat [36, 37] and cow [20] [21] [22] . In bovine species, APLNR, but not APLN mRNA, was expressed in the granulosa cells of follicles at different developmental stages, whereas both APLN and APLNR mRNA was expressed in theca cells [21] . In our study, we showed that hGCs express APLN, suggesting that the expression is specific to the species. Our data suggest that APLN and APLNR are expressed in both nuclei and cytoplasm of granulosa cells. Even if these data need to be confirmed, APLN and APLNR have been already detected in the nuclear but also in the cytoplasm of different types of cells (endothelial cells [38] , epithelial cells of the respiratory bronchi [39] , cytotrophoblast cells [40] , and neuronal cells [41] ). Shimizu et al. [21] did not investigate the presence of the APLN system (APLN and APLNR) in bovine oocyte. Mice lacking the APLNR or APLN genes are viable and fertile [42, 43] . Consistent with several adipokines, it is possible that the absence of APLN or APLNR can be compensated for by other adipokines. There is evidence in the literature that APLN plays a key role in the regulation of cell apoptosis and angiogenesis, including in the ovary. Indeed, some data show that APLN-13 significantly attenuates or protects against apoptosis in vivo in the brain or cardiac tissues after ischemia/reperfusion in mice [35, 44] , and also in vitro in PC12 cells in response to corticosterone [34] . Furthermore, a recent study reported that APLN can promote the in vitro proliferation of rat granulosa cells and inhibit apoptosis via the PI3K/Akt signaling pathway [45] . In our study, we observed strong immunoreactivity of APLNR in oocytes at different follicular stages and also in granulosa cells. From their study on bovine ovarian cells, Shimizu et al. [21] suggested that the APLN system in human ovarian cells could be involved in the regulation of apoptosis, particularly in the follicular atresia. In bovine granulosa cells, the expression of APLNR mRNA has been found to be significantly increased when granulosa cell apoptosis was induced. In our study, we investigated the effect of rh APLN on in vitro primary hGC cell proliferation and M) on the phosphorylation of AKT (E), MAPK14 (F), and MAPK3/1 (G) in response to IGF1 in primary hGCs. Primary hGCs were cultured in a media containing serum, then cultured in serum-free media for 48 h in the presence or absence of rh APLN-13 (10 À9 M), which were the same conditions used to measure progesterone and estradiol production. They were then stimulated with IGF1 (10 À8 M) for 10 min (E and F) or 1 min (G). Cells were lysed, and the lysates were directly subjected to immunoblotting with antibodies against phospho-AKT (E), anti-phospho-MAPK14 (F), or antiphospho-MAPK3/1 (G). The AKT, MAPK14, and MAPK3/1 levels were evaluated by reprobing the membranes with antibodies for total Akt, MAPK14, and MAPK3/1, respectively. Representative blots from four different cultures are shown. Each culture was performed using cells obtained from different follicles of six patients. For each culture, each of the treatments (rh APLN-13 in the presence or absence of IGF1) was conducted in duplicate. Blots were quantified, and the phosphorylated protein to total protein ratio is shown. The results are represented as mean 6 SEM.
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viability in the basal state and in response to IGF1, FSH, or LH; however, we did not observe any effects of APLN-13 or APLN-17 on these cellular processes. Thus, our results are in contrast to those presented by Shimizu et al. [21] in bovine granulosa cells. In their study, Shimizu et al. did not stimulate bovine granulosa cells with APLN; instead, they compared two events (apoptosis and variation in APLNR expression). Furthermore, they used primary granulosa cells from small follicles (5-6 mm), whereas we cultivated luteinized hGCs collected from pre-ovulatory follicles during oocyte retrieval for IVF.
In our study, we showed that APLN gene expression was not affected by IGF1, whereas the receptor was affected.
Furthermore, we observed that FSH and LH had no effect on either APLN or its receptor. In contrast, several previous studies reported that APLN mRNA levels in adipose cells were regulated by several different factors, such as fasting and refeeding and insulin concentration [9, 13] . In the present study, we showed that both rh APLN-13 and APLN-17 increased steroid production and HSD3B protein levels in response to IGF1 in hGCs. Furthermore, these effects were found to be reversed when the cells were preincubated with ML221, an antagonist of APLNR, suggesting a specific effect of APLN. In the present study, we observed no effect of rh APLN-13 and APLN-17 on the protein levels of CYP11A1, CYP19A1, and STAR, suggesting a specific effect of APLN on A) The culture medium was then collected and analyzed for progesterone content. The results are expressed as protein concentration per well (ng/ml). The results are presented as the mean 6 SEM of three independent groups of hGCs collected from six patients. Bars with different letters are significantly different (P , 0.05). B) Protein extracts from human GCs were analyzed by immunoblotting using antibodies against the HSD3B protein. Equal protein loading was verified by reprobing the membranes with an anti-VINCULIN antibody. The results were representative of at least three independent experiments. Blots were quantified, and the HSD3B to VINCULIN ratio is shown. The results are expressed as mean 6 SEM. Different letters indicate significant differences (P , 0.05).
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the HSD3B. We have no explanation for this result; however, it will be interesting to investigate the effect of rh APLN on the activity on the CYP11A1 and CYP19A1.The dose of rh APLN-13 or APLN-17 used to stimulate hGCs was close to that determined in the FF (approximately 4 ng/ml), suggesting that there were no pharmacological effects. APLN is an adipokine that plays a critical role in energy metabolism and insulin sensitivity. Yue et al. [46] showed that deletion of the APLN gene leads to metabolic alterations in skeletal muscle, including insulin resistance and reduced glucose transport. Furthermore, injection of APLN in mice reduces glycemia and increases glucose tolerance [47] . Thus, APLN exerts effects that mimic insulin in skeletal muscle. IGF1 and the IGF1R have similar structures to insulin and the insulin receptor, respectively. Thus, APLN could increase IGF1 sensitivity in granulosa cells, as already described for skeletal muscle in mice. In the present study, we showed that rh APLN-13 or APLN-17 increases IGF1-induced MAPK3/1 and Akt phosphorylation, which are signaling pathways involved in the regulation of granulosa cell steroidogenesis [48, 49] . Moreover, using pharmacological inhibitors, we showed that MAPK3/1 and AKT signaling pathways are involved in the effects of rh APLN-13 on IGF1-induced steroidogenesis.
APLN exists in several isoforms ranging from 12 to 36 residues; however, most of the studies in the literature use immunoassays that do not distinguish between specific forms. In human blood plasma, the short APLN forms (APLN-13, Pyr-APLN-13, and APLN-17) have been detected [3, 50] . Using mass spectrometry, Zhen et al. [51] showed that Pyr-APLN-13 is the most prevalent isoform in human plasma. Many other forms of APLN have been identified, beyond the known bioactive isoforms, including peptides lacking one or more C-terminal residues, to make a total of 46 isoforms [51] . However, the distribution and function of the various APLN peptides remains to be determined. We chose to measure APLN-13 in the FF because this APLN isoform is one of the most active isoforms and has been previously identified in human plasma [1] and has been shown to affect adiposity in obese mice [52] . Unfortunately, we did not have access to plasma from the patients; however, we were able to determine the concentration of APLN-13 in the FF, which is partly composed of serum and is produced by the ovaries. We observed higher APLN-13 FF levels in obese women compared to nonobese women in both the PCOS and non-PCOS groups. These results are in agreement with other previous studies that showed a positive correlation between 
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APLN serum levels and BMI in both mice [9] and humans [9, 53, 54] . Furthermore, we observed that despite their BMI (obese or nonobese), PCOS patients had a higher FF APLN-13 concentration in addition to higher APLN and APLNR mRNA expression in their granulosa cells compared to control patients. Very few studies have investigated the relationship between APLN concentrations and reproductive function in humans. These studies have shown conflicting results for the comparison of APLN levels in PCOS and non-PCOS women. Chang et al. [24] observed lower serum APLN levels in women with PCOS compared to women with a healthy regular menstrual cycle, whereas Cekmez et al. [55] described higher serum levels in adolescents with PCOS compared to controls. The discrepancy between these studies may be explained by the differences in study design, including the definition of PCOS, the age of the patients, and APLN assays (the APLN forms determined in plasma are rarely indicated). Until now, no studies have analyzed the expression of APLN and APLNR in hGCs from obese or nonobese patients with or without PCOS. Our results clearly show that APLN and APLNR mRNA expression is increased in PCOS patients, and this is exacerbated in obese patients. Recent studies investigated another endogenous peptide activator of the APLNR, named Toddler or ELABELA, which was identified to play a crucial role in the embryonic development of zebrafish (Danio rerio) [15, 56] . However, the effects of Toddler/ELABELA remains to be analyzed in ovarian cells.
In conclusion, we demonstrated that APLN and APLNR were expressed in human ovarian follicles. Furthermore, we observed that the concentration of APLN-13 in the FF and the mRNA expression of APLN and APLNR in hGCs were higher in patients with PCOS than in control patients. In primary hGCs from control patients (nonobese without PCOS), we showed that rh IGF1 increased APLNR mRNA and protein expression in a dose-dependent manner. Furthermore, rh APLN (13 and 17) increased progesterone and estradiol secretion in a dose-dependent manner in both the basal state and in response to IGF1, and these effects were reversed by using ML221, an antagonist of APLNR. This was associated with an increase in HSD3B protein concentration and AKT and MAPK3/1 phosphorylation. Therefore, APLN and APLNR may play a role in human follicular development and also in the pathogenesis of PCOS.
